How to conduct a dose response trial of Parkinson's disease medication  by Morris, Meg et al.
With the rapid increase in the prevalence of 
Parkinson's disease in Australia, it is becoming 
increasingly common for neurologists to refer 
patients to a physiotherapist for a "dose 
response trial" (DRT) to determine the short 
duration response to medication. This article 
provides a step-by-step guide on howto perform 
a DRT in the in-patient ward setting. 
[Morris M, Churchyard A and lansek R: How to 
conduct a dose response trial of Parkinson's 
disease medication. Australian Journal of 
Physiotherapy 44: 131-133] 
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How to conduct a dose 
response trial of 
Parkinson's disease 
medication 
ose response trials are drug 
challenges that enable clinicians 
to determine the person's 
responsiveness to a particular 
medication used in the treatment of 
Parkinson's disease. They are used for 
three main reasons. Firstly, they assist 
'the neurologist to make a diagnosis. If 
the person shows a good motor 
response to levodopa or apomorphine, 
there is a high likelihood that they 
have idiopathic Parkinson's disease. On 
the other hand, if the person fails to 
demonstrate any changes in motor 
performance they may well have 
another disease, such as multiple 
system atrophy, frontal gait apraxia or 
progressive supranuclear palsy. In very 
rare cases, the person does have 
idiopathic Parkinson's disease but they 
are a non-responder. The diagnosis is 
made on the basis of the clinical 
examination, history, observed 
progression of movement disorders 
and cognitive impairment over a 
period of months, together with the 
test dose response results. 
The second use of test dose response 
trials is to enable clinicians to 
determine the extent to which different 
movement disorders respond to 
medication. For example, in some 
people the speed of upper limb 
movement increases and the tremor 
decreases with levodopa even though 
postural instability and gait deviations 
fail to improve. In others, the footstep 
pattern may normalise with levodopa 
and apomorphine although speech and 
swallowing do not respond. In the 
newly diagnosed patient, motor 
performance during speech, 
swallowing, gait and ADL tasks may 
return to normal with even a small 
dose oflevodopa. 
Third, the neurologist may want to 
target a particular motor deficit (for 
example increase the medication dose 
until the person can swallow safely) but 
needs to check that dyskinesia and 
other unwanted side effects do not 
occur as a result. The test dose 
response trial is conducted to check 
that the person is not over-medicated, 
causing extra movements; or under-
medicated, which leads to poverty of 
movement. 
How is a dose response 
trial conducted? 
There are five major steps in 
conducting a trial: (i) determination of 
medication to be used for the test dose 
(ii) selection of movement disorders to 
be evaluated (iii) selection of 
measurement tools (iv) conduct of the 
test (v) presentation of findings. 
(i) Dete1'1tline the medication to be tested 
The neurologist is responsible for 
ascertaining the type and dosage of 
medication to use for the challenge 
and, if the person is a hospital in-
patient, writes up the test dose in the 
"once only" section of the medication 
charts. The next step is to decide 
whether the aim of the DRT is to: (i) 
quantify the short term response to the 
person's usual medication (ii) measure 
the onset and severity of dyskinesia or 
(iii) determine whether the person is a 
"non-responder". For the first aim, the 
person is administered their usual dose 
of levodopa, whereas for the other two 
aims, they are given a higher dose than 
usual in order to evaluate 
responSIveness. 
Most often levodopa or apomorphine 
are used for the challenge, with oral 
levodopa (Sinemet 250125 or Madopar 
200/50) a common choice. 
Apomorphine does, however, provide a 
good prediction of dopa-sensitivity and 
is quick to take effect because, unlike 
levodopa, it does not have to be 
converted to dopamine by the 
substantia nigra cells (refer to Morris 
et aI1998). The response to 
subcutaneous apomorphine occurs 
within 10 minutes and lasts for one 
hour. It has at least a 90 per cent 
response in people sensitive to 
levodopa. Notwithstanding, if 
apomorphine is used, the person has to 
take large doses of motilium to prevent 
vomiting. 
(ii) Selection of movement disorders to be 
evaluated 
Due to the limited time available for 
each test, and the potential for fatigue, 
only a small number of tests (3-4) can 
be used to chart change over time. At 
the Movement Disorders Clinic at the 
Kingston Centre in Melbourne, 
physiotherapists usually test for the 
presence and severity of hypokinesia 
(reduced movement speed and 
amplitude), dyskinesia (extra 
movements which can be choreiform 
or athetoid in type), and disability. The 
evaluation should, however, be tailored 
to match the needs of the individual. 
For example, if the person has severe 
tremor, postural instability or dystonia, 
these disorders should be evaluated in 
the dose response trial. This process is 
discussed in more detail in Morris et al 
(1998). 
(iii) Selection of measurement tools 
Once the variables for measurement 
have been determined, the 
physiotherapist can select the most 
appropriate measurement tools. Table 
3 in Morris et al (1998) summarises the 
range of tools used by clinicians to 
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evaluate motor performance. It is 
preferable for them to be quick and 
easy to administer and to have 
established reliability and validity. 
At the Kingston Centre, the most 
frequently used battery of tests 
includes the Timed Up and Go test 
(Podsialdo et aI1993); Purdue 
Pegboard test; dyskinesia rating scale, 
together with visual observation of the 
person's ability to perform rapidly 
alternating movements or repetitive 
hand tapping. This combination 
provides an indication of gait disability, 
hypokinesia and dyskinesia. The 
Hoehn and Yahr scale (1967), Unified 
Parkinson's Disease Rating scale 
(UPDRS) (Fahn et a11987) or 
modified Webster scale (Kempster et 
al 1989) can be used in addition to the 
other measures. The 10m walk test 
can also be used instead of the Timed 
Up and Go test. Because a validated 
test of dyskinesia has not previously 
been published, clinicians at the 
Kingston Centre currently subjectively 
score people on the clinical scale 
devised by Iansek (1997) as follows: 
Dyskinesia observed during functional 
movements is: 
o - non-existent 
1 - mild, present with muscle co-
activation only 
2 - present at rest, mild, does not 
interfere with voluntary motor 
activity 
3 - moderate; causing interference 
with voluntary motor activity 
4 - severe/violent 
(iv) Procedure for tbe test 
On the day before the challenge, the 
physiotherapist carefully explains the 
purpose and procedures to the person 
and their care-givers and obtains 
consent to proceed. The person is 
informed that they are to fast from 
midnight before the day of the test 
dose but they may drink water as 
required. All anti parkinsonian 
medications (except Domperidone) are 
withheld from the midnight before the 
test and during the procedure, and the 
person remains fasting except for 
water. It is important that the 
physiotherapist is with the person at 
least 30 minutes before the challenge 
in order to obtain two baseline points 
before the medication is taken. 
Immediately the medication is taken, 
the next measure is obtained. 
Subsequent measures are taken every 
15 minutes throughout the medication 
cycle, which is typically four hours in 
duration. If the person reaches a 
plateau in performance (often after 60-
120 minutes), 30min measures can be 
taken rather than 15min measures. 
However, stability needs to be 
confirmed by at least three stable 
consecutive data points before the 
spacing of measurement is increased. 
As well as monitoring motor 
fluctuations, the physiotherapist 
provides reassurance and psychological 
support. The person returns to their 
normal diet and medication once the 
test dose is completed and the results 
are filed in the physiotherapy section 
of the patient file as well as mailed to 
the neurologist. 
(v) Presenting tbe findings 
The results need to be presented 
clearly in a manner that is easy for 
other health professionals to interpret. 
It is useful for the neurologist to have a 
copy of the raw data in table format. A 
brief written report should also 
accompany the results. Figure 1 
provides an example of a physiotherapy 
report on the results of a test dose 
response trial. 
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Dose Response Trial: Midi. B. (1lcU.eu, :bakolBvdI.) 
Duration of Parkinson's disease: 16~ 
Past History: PdIJIlia&U 
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1. Purdue Pegboard test (number of pegs in 30s; normative value = 15) 
2. Timed Up and Go test (stand up, walk 3m, turn around, walk back and sit down; normative value = 8s) 
skinesia: 
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Figure 1. Exampie of a physiotherapy dose respOlise trial repm1: 
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